These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 10540766)

  • 21. Low-dose instillation therapy with bacille Calmette-Guérin Tokyo 172 strain after transurethral resection: historical cohort study.
    Yoneyama T; Ohyama C; Imai A; Ishimura H; Hagisawa S; Iwabuchi I; Mori K; Kamimura N; Koie T; Yamato T; Suzuki T
    Urology; 2008 Jun; 71(6):1161-5. PubMed ID: 18279920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder.
    Mack D; Höltl W; Bassi P; Brausi M; Ferrari P; de Balincourt C; Sylvester R;
    J Urol; 2001 Feb; 165(2):401-3. PubMed ID: 11176382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression.
    Andius P; Holmäng S
    BJU Int; 2004 May; 93(7):980-4. PubMed ID: 15142147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes after intravesical bacillus Calmette-Guerin are not affected by substaging of high grade T1 transitional cell carcinoma.
    Kondylis FI; Demirci S; Ladaga L; Kolm P; Schellhammer PF
    J Urol; 2000 Apr; 163(4):1120-3. PubMed ID: 10737479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
    de Reijke TM; Kurth KH; Sylvester RJ; Hall RR; Brausi M; van de Beek K; Landsoght KE; Carpentier P;
    J Urol; 2005 Feb; 173(2):405-9. PubMed ID: 15643181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
    Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML
    Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis.
    Uchida A; Yonou H; Hayashi E; Iha K; Oda M; Miyazato M; Oshiro Y; Hokama S; Sugaya K; Ogawa Y
    Urology; 2007 Feb; 69(2):275-9. PubMed ID: 17320663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant intravesical treatment of superficial bladder cancer with a standardized mistletoe extract.
    Elsässer-Beile U; Leiber C; Wolf P; Lucht M; Mengs U; Wetterauer U
    J Urol; 2005 Jul; 174(1):76-9. PubMed ID: 15947582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
    Fujimoto K; Chihara Y; Kondo H; Hirao Y
    Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients.
    Orsola A; Trias I; Raventós CX; Español I; Cecchini L; Búcar S; Salinas D; Orsola I
    Eur Urol; 2005 Aug; 48(2):231-8; discussion 238. PubMed ID: 15963635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Adjuvant BCG immunotherapy in the management of superficial bladder tumors].
    Somogyi L; Szántó A; Polyák L; Baranyay F; Drinóczy M
    Orv Hetil; 1993 Aug; 134(34):1851-6. PubMed ID: 8355975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The safety and efficacy of different doses of bacillus Calmette Guérin in superficial bladder transitional cell carcinoma.
    Agrawal MS; Agrawal M; Bansal S; Agarwal M; Lavania P; Goyal J
    Urology; 2007 Dec; 70(6):1075-8. PubMed ID: 18158020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer-a multicentre clinical phase III study].
    Jocham D; von Wietersheim J; Pflüger H; Steiner H; Doehn C; Büttner H; Böhle A; Kausch I
    Aktuelle Urol; 2009 Mar; 40(2):91-9. PubMed ID: 19214951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low dose BCG as adjuvant therapy for superficial bladder cancer and literature review.
    Cheng CW; Ng MT; Chan SY; Sun WH
    ANZ J Surg; 2004 Jul; 74(7):569-72. PubMed ID: 15230793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cytoscopic follow-up of initial G3T1 bladder tumors treated with BCG].
    Pieras Ayala E; Palou J; Rodríguez-Villamil L; Millán Rodríguez F; Salvador Bayarri J; Vicente Rodríguez J
    Arch Esp Urol; 2001 Apr; 54(3):211-7. PubMed ID: 11432035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Tolerance and efficiency of intravesical instillation of Calmette-Guérin in the prophylactic treatment of superficial bladder tumors, using a maintenance treatment].
    Saint F; Irani J; Salomon L; Debois H; Abbou CC; Chopin D
    Prog Urol; 2001 Sep; 11(4):647-56. PubMed ID: 11761685
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony].
    Steinbach F; Schuster F
    Aktuelle Urol; 2005 Aug; 36(4):337-41. PubMed ID: 16110407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.